The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Breyanzi lisocabtagene maraleucel PRIMEATMPAdditional monitoring | Bristol-Myers Squibb Pharma EEIG | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Mediastinal Neoplasms | 🇪🇺 EU 2022-04-04 | Order → |
| Kimmtrak tebentafusp OrphanAdditional monitoring | Immunocore Ireland Limited | Uveal Neoplasms | 🇪🇺 EU 2022-04-01 | Order → |
| Stimufend pegfilgrastim BiosimilarAdditional monitoring | Fresenius Kabi Deutschland GmbH | 🇪🇺 EU 2022-03-28 | Order → | |
| Evusheld tixagevimab;cilgavimab Additional monitoring | AstraZeneca AB | COVID-19 virus infection | 🇪🇺 EU 2022-03-25 | Order → |
| Dasatinib Accord dasatinib (anhydrous) Generic | Accord Healthcare S.L.U. | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2022-03-24 | Order → |
| Dasatinib Accordpharma dasatinib (anhydrous) Generic | Accord Healthcare S.L.U. | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 🇪🇺 EU 2022-03-24 | Order → |
| Sondelbay teriparatide BiosimilarAdditional monitoring | Accord Healthcare S.L.U. | Osteoporosis | 🇪🇺 EU 2022-03-24 | Order → |
| Vildagliptin / Metformin hydrochloride Accord vildagliptin;metformin hydrochloride Generic | Accord Healthcare S.L.U. | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2022-03-24 | Order → |
| Ontilyv opicapone | Bial Portela & Companhia S.A. | Parkinson Disease | 🇪🇺 EU 2022-02-21 | Order → |
| Kerendia finerenone Additional monitoring | Bayer AG | Renal Insufficiency, Chronic; Diabetes Mellitus, Type 2; Heart Failure | 🇪🇺 EU 2022-02-16 | Order → |
| Sapropterin Dipharma sapropterin Generic | Dipharma Arzneimittel GmbH | Phenylketonurias | 🇪🇺 EU 2022-02-16 | Order → |
| Sitagliptin / Metformin hydrochloride Mylan sitagliptin hydrochloride monohydrate;metformin hydrochloride Generic | Mylan Pharmaceuticals Limited | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2022-02-16 | Order → |
| Tepmetko tepotinib Additional monitoring | Merck Europe B.V. | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2022-02-16 | Order → |
| Ngenla somatrogon OrphanAdditional monitoring | Pfizer Europe MA EEIG | Growth and Development | 🇪🇺 EU 2022-02-14 | Order → |
| Okedi risperidone | Laboratorios Farmacéuticos Rovi, S.A. | Schizophrenia | 🇪🇺 EU 2022-02-14 | Order → |
| Oxbryta voxelotor OrphanPRIMEAdditional monitoring | Pfizer Europe MA EEIG | Anemia; Anemia, Hemolytic; Anemia, Sickle Cell | 🇪🇺 EU 2022-02-14 | Order → |
| Prevenar 20 (previously Apexxnar) pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed) Additional monitoring | Pfizer Europe MA EEIG | Pneumococcal Infections | 🇪🇺 EU 2022-02-14 | Order → |
| Saphnelo anifrolumab Additional monitoring | AstraZeneca AB | Lupus Erythematosus, Systemic | 🇪🇺 EU 2022-02-14 | Order → |
| Paxlovid nirmatrelvir;ritonavir | Pfizer Europe MA EEIG | COVID-19 virus infection | 🇪🇺 EU 2022-01-28 | Order → |
| Vyepti eptinezumab | H. Lundbeck A/S | Migraine Disorders | 🇪🇺 EU 2022-01-24 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.